financetom
Business
financetom
/
Business
/
Investor files liquidation petition in China against Evergrande unit
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Investor files liquidation petition in China against Evergrande unit
Aug 8, 2024 11:04 PM

HONG KONG (Reuters) -An investor has filed a petition in a Chinese court to liquidate a major onshore unit of heavily indebted property developer China Evergrande, a stock filing by the petitioner showed on Wednesday.

Vanward, a Shenzhen-listed electric appliance manufacturer, cited a dispute with Evergrande unit Guangzhou Kailong Real Estate over an investment worth 200 million yuan ($27.9 million).

A court in the southern Chinese city of Guangzhou is reviewing Vanward's case, the filing said.

Vanward won an arbitrary ruling in Shenzhen in December 2022 that called on Kailong to return the investment with interest accrued and legal costs. Kailong has yet to comply, Vanward said in its filing.

The petition comes after a Hong Kong court in January ordered China Evergrande, the offshore holding company of the onshore units, to be liquidated after failing to provide a satisfactory restructuring plan for $23 billion in offshore debt. A Hong Kong liquidation order, however, is not automatically recognised in mainland China.

A spokesperson for the liquidators of Evergrande declined to comment on the petition.

Evergrande said in a statement to Reuters a bankruptcy of Kailong would not affect the normal operations of Hengda Real Estate - Evergrande's flagship property entity in mainland China - including its completion and delivery of homes to buyers.

Evergrande said Kailong is the holding platform of Hengda and it does not operate any property projects. Kailong controls a 60.3% stake in Hengda, business registry database Qichacha shows.

On Monday, Evergrande's electric vehicle unit said a Chinese court had ruled that two of its subsidiaries must enter bankruptcy and be reorganised.

Evergrande was once China's largest property developer and has more than $300 billion in liabilities.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Moody's upgrades New York Bancorp's long-term rating to B2
Moody's upgrades New York Bancorp's long-term rating to B2
Mar 15, 2024
March 15 (Reuters) - Ratings agency Moody's said on Friday it has upgraded New York Community Bancorp's ( NYCB ) long-term issuer rating to B2. ...
Hims & Hers Health Insider Sold Shares Worth $965,016, According to a Recent SEC Filing
Hims & Hers Health Insider Sold Shares Worth $965,016, According to a Recent SEC Filing
Mar 15, 2024
04:15 PM EDT, 03/15/2024 (MT Newswires) -- Soleil Boughton, Chief Legal Officer, on March 13, 2024, sold 63,621 shares in Hims & Hers Health ( HIMS ) for $965,016. Following the Form 4 filing with the SEC, Boughton has control over a total of 154,345 shares of the company, with 154,345 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1773751/000177375124000059/xslF345X03/wk-form4_1710533549.xml ...
Hologic Insider Sold Shares Worth $1,241,296, According to a Recent SEC Filing
Hologic Insider Sold Shares Worth $1,241,296, According to a Recent SEC Filing
Mar 15, 2024
04:16 PM EDT, 03/15/2024 (MT Newswires) -- Scott T Garrett, Director, on March 14, 2024, sold 16,441 shares in Hologic ( HOLX ) for $1,241,296. Following the Form 4 filing with the SEC, Garrett has control over a total of 48,611 shares of the company, with 48,611 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/859737/000112760224010261/xslF345X03/form4.xml Price: 75.92, Change: +0.01, Percent Change: +0.01...
Avidity Biosciences Insider Sold Shares Worth $980,760, According to a Recent SEC Filing
Avidity Biosciences Insider Sold Shares Worth $980,760, According to a Recent SEC Filing
Mar 15, 2024
04:16 PM EDT, 03/15/2024 (MT Newswires) -- Michael F MacLean, Chief Financial Officer, on March 13, 2024, sold 40,000 shares in Avidity Biosciences ( RNA ) for $980,760. Following the Form 4 filing with the SEC, MacLean has control over a total of 44,093 shares of the company, with 44,093 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1599901/000159990124000044/xslF345X03/wk-form4_1710533514.xml ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved